FDA approves tremelimumab with durvalumab for advanced liver cancer

The FDA approved tremelimumab in combination with durvalumab for adults with unresectable hepatocellular carcinoma.Tremelimumab (Imjudo, AstraZeneca) is an anti-CTLA-4 monoclonal antibody. Durvalumab (Imfinzi, AstraZeneca) is a human monoclonal antibody that binds to PD-L1.The FDA based the approval on the results of the randomized phase 3 HIMALAYA trial, which included 1,324 patients with unresectable HCC who had not received prior systemic therapy and were ineligible for localized treatment.Researchers assigned patients to one of three treatment regimens: durvalumab monotherapy; the STRIDERead More